XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
3 Months Ended
Apr. 29, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

6. Stock-Based Compensation

The Company has one active stock-based compensation plan: the 2016 Incentive Compensation Plan (as amended, the “2016 Plan”). The initial share reserve under the 2016 Plan was 5,725,538 shares of common stock. A grant of a stock option award or stock appreciation right will reduce the outstanding reserve on a one-for-one basis, meaning one share for every share granted. A grant of a full-value award, including, but not limited to, restricted stock, restricted stock units and deferred stock, will reduce the outstanding reserve by a fixed ratio of 1.9 shares for every share granted. The Company’s shareholders approved amendments to increase the share reserve by 2,800,000 shares on August 8, 2019, an additional 1,740,000 shares on August 12, 2020 and an additional 4,855,000 on August 5, 2021. At April 29, 2023, the Company had 3,916,695 shares available under the 2016 Plan.

In accordance with the terms of the 2016 Plan, any shares outstanding under the previous 2006 Incentive Compensation Plan (the “2006 Plan”) at August 4, 2016 that subsequently terminate, expire or are cancelled for any reason without having been exercised or paid are added back and become available for issuance under the 2016 Plan, with stock options being added back on a one-for-one basis and full-value awards being added back on a 1 to 1.9 basis. At April 29, 2023, 108,602 stock options remained outstanding under the 2006 Plan.

The 2016 Plan is administered by the Compensation Committee. The Compensation Committee is authorized to make all determinations with respect to amounts and conditions covering awards. Options are not granted at a price less than fair value on the

date of the grant. Except with respect to 5% of the shares available for awards under the 2016 Plan, no award will become exercisable unless such award has been outstanding for a minimum period of one year from its date of grant.

The following tables summarize the share activity and stock option activity for the first three months of fiscal 2023:

 

 

 

RSUs (1)

 

 

Deferred
shares
(2)

 

 

Performance
Share Units
(3)

 

 

Fully-Vested
 Shares
(4)

 

 

Total number
of shares

 

 

Weighted-
average
grant-date
fair value

 

Shares

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding non-vested shares at beginning of year

 

 

520,008

 

 

 

435,568

 

 

 

240,000

 

 

 

 

 

 

1,195,576

 

 

$

2.51

 

Shares granted

 

 

270,867

 

 

 

 

 

 

 

 

 

2,844

 

 

 

273,711

 

 

$

5.21

 

Shares vested and/or issued

 

 

(250,547

)

 

 

 

 

 

 

 

 

(2,844

)

 

 

(253,391

)

 

$

2.70

 

Shares expired

 

 

 

 

 

 

 

 

(240,000

)

 

 

 

 

 

(240,000

)

 

$

1.07

 

Shares forfeited

 

 

(50,612

)

 

 

 

 

 

 

 

 

 

 

 

(50,612

)

 

$

7.35

 

Outstanding non-vested shares at end of quarter

 

 

489,716

 

 

 

435,568

 

 

 

 

 

 

 

 

 

925,284

 

 

$

3.37

 

 

(1)
During the first three months of fiscal 2023, the Company granted RSUs for the achievement of performance metrics under the 2020-2022 LTIP that are subject to additional vesting through August 31, 2023. See Note 5, Long-Term Incentive Plans. As a result of net share settlements, of the 250,547 RSUs that vested, only 169,517 shares of common stock were issued.
(2)
The outstanding deferred shares will be issued upon the director’s separation from service.
(3)
Represents the remaining performance stock units (“PSUs”) granted to Mr. Kanter in February 2019 which expired unvested on April 1, 2023.
(4)
Represents compensation, with a fair value of $20,249, to certain directors, who are required to receive shares, in lieu of cash, in order to satisfy their minimum equity ownership under the Non-Employee Director Plan. Voluntary shares received, in lieu of cash, are reported below under Non-Employee Director Compensation Plan.

 

 

 

Number of
shares

 

 

Weighted-
average
exercise price
per option

 

 

Weighted-
average
remaining
contractual term

 

 

Aggregate
intrinsic value

 

Stock Options

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding options at beginning of year

 

 

3,556,434

 

 

$

0.83

 

 

7.4 years

 

 

$

23,238,665

 

Options granted

 

 

1,316

 

 

$

5.92

 

 

 

 

 

 

 

Options exercised

 

 

(80,960

)

 

$

2.66

 

 

 

 

 

 

227,903

 

Options expired and canceled

 

 

(12,892

)

 

$

2.42

 

 

 

 

 

 

49,037

 

Outstanding options at end of quarter

 

 

3,463,898

 

 

$

0.78

 

 

7.1 years

 

 

$

12,616,891

 

Options exercisable at end of quarter

 

 

2,204,631

 

 

$

0.84

 

 

6.9 years

 

 

$

7,925,550

 

 

For the first three months of fiscal 2023, the Company granted stock options to purchase an aggregate of 1,316 shares of common stock, 270,867 restricted stock units and 2,844 fully-vested shares. For the first three months of fiscal 2022, the Company granted stock options to purchase an aggregate of 2,040 shares of common stock, 494,444 restricted stock units and 9,352 fully-vested shares.

Non-Employee Director Compensation Plan

The Company granted 12,376 shares of common stock, with a fair value of approximately $88,117, to certain of its non-employee directors as compensation in lieu of cash in the first three months of fiscal 2023. These shares are in addition to any shares that may be granted under the 2016 Plan related to the requirement to receive equity if a director has not yet satisfied his or her minimum equity ownership requirement under the Non-Employee Director Compensation Plan.

Stock Compensation Expense

The Company recognized total stock-based compensation expense of $0.4 million and $0.4 million for the first three months of fiscal 2023 and fiscal 2022, respectively. The total compensation cost related to time-vested stock options and RSU awards not yet recognized as of April 29, 2023 was approximately $1.7 million, net of estimated forfeitures, which will be expensed over a weighted average remaining life of 27 months.